To say this is a disappointing result would be and understatement.
What I don't get is this
'measures of circulating cytokines and inflammatory markers will be evaluated. None of these were included in the interim analysis'
Why not?
If SOC has improved that much over the past 6 months or so, why is the death rate still climbing to record levels (in US)?
I can see the patient about to take his/her last breath and pointing to the Rem-L set-up. Sorry, not considered good enough!
The drug(sic) still works
There must be more detail in the data to follow.
This is just an extension of their main game for ARDS
I'll wait
hakuna matata
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-331
-
- There are more pages in this discussion • 745 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |